王翔，教授，主任医师，博士生导师，现任国家癌症中心/中国医学科学院肿瘤医院乳腺外科主任。自上世纪八十年代中期至今，从医近四十年，深耕临床工作，医术精益求精，擅长乳腺癌保乳术、改良根治术术和乳房再造术等手术治疗及多学科综合诊疗，曾获得我国外科学最高奖"敬佑生命·荣耀医者"中的"金柳叶刀奖"和"京城好医生"以及第六届“国之名医.卓越建树”等荣誉称号。并获得2017年北京市科学技术三等奖和2018年华夏医学科技三等奖。担任中国临床肿瘤学会(CSCO)乳腺癌专家委员会常委，北京肿瘤学会乳腺外科专业委员会首任主任委员、北京乳腺病防治学会外科专业委员会主任委员等学术职务，是国家卫健委2018版《乳腺癌诊治规范》的主要执笔人和最终定稿人，牵头制订和参与了我国乳腺癌多项诊疗指南。作为国际权威乳腺癌研究机构--早期乳腺癌试验协作组(EBCTCG)中国代表，参与多项国际多中心临床研究，相关成果12次发表于Lancet和NEJM等知名刊物，改进了世界和我国乳腺癌治疗。在国内外专业期刊上发表论著94篇，近5年来以第一作者和通讯作者发表SCI论文30篇，总影响因子210+，承担课题十余项。

科研课题

1、北京市科学技术委员会“乳腺癌早期筛查与规范化治疗关键技术研究”项目，SCW2016-26，乳腺癌保留乳房手术联合术中放射治疗的队列研究，2016/01-2019/12，210万元，在研，主持。

2、国家自然科学基金青年科学基金项目，81802669，DNA修复通路基因复合突变对遗传性乳腺癌-卵巢癌综合征中表型扩展的作用与机制研究，2019/01-2021/12，21万元，在研，参加。

3、国家自然科学基金青年科学基金项目，81602343，基于循环肿瘤DNA的乳腺癌腋窝淋巴结转移分子标记物研究，2017/01-2019/12，17万元，在研，参加。

4、首都卫生发展科研专项项目青年项目，乳腺癌新辅助化疗后前哨淋巴结活检的可行性研究，2016/01-2018/12，13万元，已结题，参加。

5、国家重点基础研究发展计划(973计划)，2014CB744505，基于影像实时动态多元分子分型的乳腺癌精准治疗疗效评估和诊疗一体化研究协作单位，2014/01-2019/12，20万，已结题，参加。

6、卫生公益性行业科研专项，201502027，乳腺增生症诊疗规范的修订协作单位，2015/01-2017/12，22.8万，已结题，参加。

代表性科研成果

1. 王翔(1/6), 早期乳腺癌综合治疗关键技术的建立、规范化及推广, 北京市科委, 北京市科学技术奖, 三等奖, 2017

2. 王翔(1/8), 早期乳腺癌综合治疗关键技术的应用与经济学评估，中国医疗保健国际交流促进会，华夏医学科技奖，三等奖，2018

以第一作者或通讯作者发表的SCI论文

1. Liu J, Chen H, Li Y, Fang Y, Guo Y, Li S, Xu J, Jia Z, Zou J, Liu G, Xu H, Wang T, Wang D, Jiang Y, Wang Y, Tang X, Qiao G, Zhou Y, Bai L, Zhou R, Lu C, Wen H, Li J, Huang Y, Zhang S, Feng Y, Chen H, Xu S, Zhang B*, Liu Z*, Wang X*. A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer. J Hematol Oncol. 2023 Jun 16;16(1):63. (IF=28.5，并列通讯作者)

2. Liu G, Xing Z, Guo C, Dai Q, Cheng H, Wang X, Tang Y, Wang Y. Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study. Front Oncol. 2023 Aug 4;13:1217869. (IF=4.7，并列通讯作者)

3. Li J, Liu G, Jia Z, Ren F, Dong D, Zhang M, Wang X*, Wang Y*. Occult breast cancer patients with mastectomy have better prognosis than those with breast-conserving therapy. Future Oncol. 2023 Nov;19(36):2405-2416. (IF=3.3，通讯作者)

4. Xing Z, Lin D, Hong Y, Ma Z, Jiang H, Lu Y, Sun J, Song J, Xie L, Yang M, Xie X, Wang T, Zhou H, Chen X, Wang X*, Gao J*. Construction of a prognostic 6-gene signature for breast cancer based on multi-omics and single-cell data. Front Oncol. 2023 Nov 21;13:1186858. (IF=4.7，并列通讯作者)

5. Ren F, Shang Q, Zhao S, Yang C, Feng K, Liu J, Kang X, Zhang R, Wang X*, Wang X*. An exploration of the correlations between seven psychiatric disorders and the risks of breast cancer, breast benign tumors and breast inflammatory diseases: Mendelian randomization analyses. Front Psychiatry. 2023 Jun 28;14:1179562. (IF=4.7，并列通讯作者)

6. Feng K, Zhao S, Shang Q, Liu J, Yang C, Ren F, Wang X*, Wang X*. An overview of the correlation between IPI and prognosis in primary breast lymphoma. Am J Cancer Res. 2023 Jan 15;13(1):245-260. (IF=5.3，并列通讯作者)

7. Ren F, Zhao S, Yang C, Liu J, Shang Q, Feng K, Kang X, Zhang R, Wang X*, Wang X*. Applications of photodynamic therapy in extramammary Paget's disease. Am J Cancer Res. 2023 Oct 15;13(10):4492-4507. (IF=5.3，并列通讯作者)

8. Feng K, Ren F, Wang X*. Relationships among breast, gut, and oral microbiota across diverse pathological types of breast cancer, a Chinese cohort study. Front Mol Biosci. 2023 Nov 21;10:1325552. doi: 10.3389/fmolb.2023.1325552. (IF=5.0，通讯作者)

9. Feng K, Xing Z, Dai Q, Cheng H, Wang X*. Role of aggressive locoregional surgery in treatment strategies for ipsilateral supraclavicular lymph node metastasis of breast cancer: a real-world cohort study. Front Mol Biosci. 2023 Oct 17;10:1248410. (IF=5.0，通讯作者)

10. Feng K, Ren F, Wang X*. Association between oral microbiome and seven types of cancers in East Asian population: a two-sample Mendelian randomization analysis. Front Mol Biosci. 2023 Nov 21;10:1327893. (IF=5.0，通讯作者)

11. Jiaqi Liu#, Hengqiang Zhao#, Yu Zheng#, Lin Dong#, Sen Zhao#, Yukuan Huang, Shengkai Huang, Tianyi Qian, Jiali Zou, Shu Liu, Jun Li, Zihui Yan, Yalun Li, Shuo Zhang, Xin Huang, Wenyan Wang, Yiqun Li, Jie Wang, Yue Ming, Xiaoxin Li, Zeyu Xing, Ling Qin, Zhengye Zhao, Ziqi Jia, Jiaxin Li, Gang Liu, Menglu Zhang, Kexin Feng, Jiang Wu, Jianguo Zhang, Yongxin Yang, Zhihong Wu, Zhihua Liu, Jianming Ying, Xin Wang, Jianzhong Su*, Xiang Wang*, Nan Wu*. DrABC: Deep Learning Accurately Predicts Germline Pathogenic Mutation Status in Breast Cancer Patients Based on Phenotype Data. Genome Medicine. 2022; 25;14(1):21. (IF=11.1，并列通讯作者)

12. Li J, Jia Z, Zhang M, Liu G, Xing Z, Wang X, Huang X, Feng K, Wu J, Wang W, Wang J, Liu J*, Wang X*. Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review. Front Oncol. 2022 Jan 10;11:763161. (IF=6.2，并列通讯作者)

13. Wang X, Feng K, Wang W, Meng X, Liu J, Yang Y, Zhong Y, Li J, Wu S, Li M, Ma P, Feng Q, Zeng H, Gu Y, Li X*, Fan Z*, Wang X*. Long-term outcomes of intraoperative radiotherapy for early-stage breast cancer in China: a multicenter real-world study. Cancer Commun (Lond). 2022 Mar;42(3):277-280. doi: 10.1002/cac2.12258. Epub 2022 Jan 19. (IF=15.28，通讯作者)

14. Jiaqi Liu#, Hengqiang Zhao#, Yukuan Huang#, Shouping Xu#, Yan Zhou, Wei Zhang, Jiaqi Li, Yue Ming, Xinyu Wang, Sen Zhao, Kai Li, Xiying Dong, Yunlong Ma, Tianyi Qian, Xinyi Chen, Zeyu Xing, Yan Zhang, Hongyan Chen, Zhihua Liu, Da Pang, Meng Zhou, Zhihong Wu, Xiaowo Wang, Xiang Wang*, Nan Wu*, Jianzhong Su*. Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer. Molecular Cancer. 2021 Feb 19;20(1):36. (IF=27.3，并列通讯作者)

15. Jiaqi Liu#, Xin Wang#, Lin Dong#, Xin Huang#, Hengqiang Zhao, Jiaxin Li, ShengKai Huang, Pei Yuan, Wenyan Wang, Jie Wang, Zeyu Xing, Ziqi Jia, Yue Ming, Xiao Li, Ling Qin, Gang Liu, Jiang Wu, Yiqun Li, Menglu Zhang, Kexin Feng, Jianming Ying*, Xiang Wang*. The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients with Germline Pathogenic Variants in Cancer Predisposition Genes. Frontiers in Oncology. 2021; 13;11:710156.(IF=6.2，并列通讯作者)

16. Zhang M#, Liu J#, Liu G#, Xing Z, Jia Z, Li J, Wang W, Wang J, Qin L, Wang X, Wang X. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies. Cancer Lett. 2021 Aug 10;520:422-433. (IF=8.7，并列通讯作者)

17. Jia Z#, Li J#, Zhang Y#, Wang X, Xing J, Xing Z, Huang X, Liu G, Zhang M, Feng K, Wu J, Wang W, Wang J, Liu J*, Wang X*. Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis. Cancer Cell Int. 2021 Sep 25;21(1):512. (IF=5.7，并列通讯作者)

18. Wang X#, Qian T#, Bao S#, Zhao H, Chen H, Xing Z, Li Y, Zhang M, Meng X, Wang C, Wang J, Gao H, Liu J*, Zhou M*, Wang X*. Circulating exosomal miR-363-5p inhibits lymph node metastasis by downregulating PDGFB and serves as a potential noninvasive biomarker for breast cancer. Mol Oncol. 2021 Sep;15(9):2466-2479. (IF=6.6，并列通讯作者)

19. Yang C, Liu J, Zhao S, Ying J, Liu Y, Ma L, Shang Q, Meng X, Feng K, Zheng B, Guo C, Wang X, Wang X. Establishment and validation of a gasdermin signature to evaluate the immune status and direct risk-group classification in luminal-B breast cancer. Clin Transl Med. 2021 Nov;11(11):e614. doi: 10.1002/ctm2.614. (IF=8.554，并列通讯作者)

20. Xing Z, Wang R, Wang X, Liu J, Zhang M, Feng K, Wang X. CircRNA circ-PDCD11 promotes triple-negative breast cancer progression via enhancing aerobic glycolysis. Cell Death Discov. 2021 Aug 21;7(1):218. doi: 10.1038/s41420-021-00604-y. (IF=3.246，并列通讯作者)

21. Xing Z, Wang X, Liu J, Liu G, Zhang M, Feng K, Wang X. Effect of MiR-210 on the Chemosensitivity of Breast Cancer by Regulating JAK-STAT Signaling Pathway. Biomed Res Int. 2021 Aug 11;2021:7703159. doi: 10.1155/2021/7703159. (IF=7.109，并列通讯作者)

22. Xing Z, Wang X, Liu J, Liu G, Zhang M, Feng K, Wang X. Effects of Ulinastatin on Proliferation and Apoptosis of Breast Cancer Cells by Inhibiting the ERK Signaling Pathway. Biomed Res Int. 2021 Jul 30;2021:9999268. doi: 10.1155/2021/9999268. (IF=3.246，并列通讯作者)

23. Xing Z, Wang X, Liu J, Zhang M, Feng K, Wang X. Expression and prognostic value of CDK1, CCNA2, and CCNB1 gene clusters in human breast cancer. J Int Med Res. 2021 Apr;49(4):300060520980647. doi: 10.1177/0300060520980647. PMID: 33896262; PMCID: PMC8076779.(IF=1.573，并列通讯作者)

24. Xing Z, Zhang M, Liu J, Liu G, Feng K, Wang X. Overexpression of IncRNA SAMMSON Promotes Triple-Negative Breast Cancer Cell Proliferation by Interacting with p53. Crit Rev Eukaryot Gene Expr. 2021;31(6):1-8. doi: 10.1615/CritRevEukaryotGeneExpr.2021039534.(IF=1.406，并列通讯作者)

25. Wang J#, Song Y#, Liu J#, Meng X, Xing Z, Zhang M, Ye F, Wang X, Wang X. Clinical Application and Feasibility of MRI-Guided Breast Biopsy of Breast Minimal Lesions in Chinese Population. Front Oncol. 2020 Mar 6;10:257. doi: 10.3389/fonc.2020.00257. (IF=4.8，并列通讯作者)

26. Feng K, Meng X, Liu J, Xing Z, Zhang M, Wang X, Feng Q, Wang X. Update on intraoperative radiotherapy for early-stage breast cancer. Am J Cancer Res. 2020 Jul 1;10(7):2032-2042. (IF=5.94，并列通讯作者)

27. Zhang M, Meng X, Guo C, Liu J, Xing Z, Wang X, Wang X. Clinicopathological Relevance and Prognostic Value of Androgen Receptor in Mammary Paget's Disease with Underlying Invasive Ductal Carcinoma. Oncol Res Treat. 2020;43(7-8):346-353. doi: 10.1159/000507893. (IF=2.844，并列通讯作者)

28. Wang W, Liu J, Wang J, Gao J, Wang X, Wang X. Impact of Locoregional Treatment on Prognosis of de novo Stage IV Breast Cancer: A Retrospective Long-Term Study of Chinese Population. Gynecol Obstet Invest. 2019;84(3):248-258(IF=2.729，通讯作者)

29. Zhang B, Wu J, Zheng R, Zhang Q, Wang MZ, Qi J, Liu H, Wang Y, Guo Y, Chen F, Wang J, Lyu W, Gao J, Fang Y, Chen W, Wang X. Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea. Chin J Cancer Res. 2018 Aug;30(4):468-476. doi: 10.21147/j.issn.1000-9604.2018.04.10. (IF=4.026，并列通讯作者)

30. Xin Wang#, Liang Li#, Jidong Gao#, Jiaqi Liu#, Mingming Guo, Liyuan Liu, Wenyan Wang, Jie Wang, Zeyu Xing, Zhigang Yu, Xiang Wang(*). The Association Between Body Size and Breast Cancer in Han Women in Northern and Eastern China[J]. The Oncologist, 2016, 21(11): 1362-1368. (通讯作者)

31. Wang Wenyan , Wang Xin, Liu Jiaqi, Gao Jidong, Wang Jie,WangXiang , Zhao Dongbing Breast cancer in young women of Chinese Han population: A retrospective study of patients under 25 years. Pathology Research and Practice. 2016.11;212(11): 1015~1020(通讯作者)

32. Zhang, Bai-Lin，Sivasubramaniam, Priya G，Zhang, Qian，Wang, Jing，Zhang, Bin，Gao, Ji-Dong，Tang, Zhong-Hua，Chen, Guo-Ji，Xie, Xiao-Ming，Wang, Zhongzhao，Yang, Hong-Jian，He, Jian-Jun，Li, Hui，Li, Jia-Yuan，Fan, Jin-Hu，Wang, Xiang*，Qiao, You-Lin*，Trends in Radical Surgical Treatment Methods for Breast Malignancies in China: A Multicenter 10-Year Retrospective Study. Oncologist,2015,20(9):1036-1043.(通讯作者)

33. 4Wang Xin，Liu Jiaqi，Wang Wenyan，Feng Qinfu，Wang Xiang(*)，Clinical analysis of intraoperative radiotherapy during breast-conserving surgery of early breast cancer in the Chinese Han population. Oncotarget,2015,6(40):43120-43126(通讯作者)

34. Zhang Bailin, Love Susan M, Chen Guoji, Wang Jing, Gao Jidong, Xu Xiaozhou, Wang Zhongzhao, Wang Xiang. The safety parameters of the study on intraductal cytotoxic agent delivery to the breast before mastectomy. Chin J Cancer Res 2014,10:26(5): 579~587(通讯作者)

35. Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X(*), Liu Z(*). MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013 Sep 5; 32(36):4294-303. (通讯作者)

36. Zhang Huiming，Zhang Zhongtao，Xuan Lixue，Zheng Shan，Guo Lei，Zhan Qimin，Qu Xiang，Zhang Baoning，Wang Yu，Wang Xiang(*)，Evaluation of ER-alpha,ER-beta 1 and ER-beta 2 expression and correlation withclinicopathologic factors in invasive luminal subtype breast cancers，Clinical and Translational Oncology，2012，14(3)：225-231(通讯作者)

37. Zhang Huiming，Zhang Baoning，Wang Zhongzhao，Bi Xiaofeng，Gao Jidong，Wang Xiang(*)，The Mid-Long Term Outcome of Breast-Conserving Patients with Different Ages，Clinical Oncology & Cancer Research，2009，6(4)：250-255(通讯作者)

以第一作者或通讯作者发表的中文论文

1. 冯轲昕,王文彦,刘佳祥, 商庆尧，杨琛轩，任斐，王昕*，王翔*. 利妥昔单抗联合CHOP方案治疗原发性乳腺淋巴瘤的疗效分析[J]. 解放军医学杂志,2023,48(2):204-210. DOI:10.11855/j.issn.0577-7402.2023.02.0204. (通讯作者)

2. 张梦璐,王昕,邢泽宇, 刘嘉琦，王翔*. 年轻乳腺佩吉特病伴浸润性导管癌患者的临床病理特征及预后分析[J]. 中华肿瘤杂志,2022,44(5):425-429. DOI:10.3760/cma.j.cn112152-20200827-00771. (通讯作者)

3. 张梦璐,邢泽宇,王昕, 刘嘉琦，刘刚，王翔*. 血管内皮生长因子在炎性乳腺癌中的应用[J]. 中华乳腺病杂志(电子版),2021,15(5):302-306. DOI:10.3877/cma.j.issn.1674-0807.2021.05.006. (通讯作者)

4. 冯轲昕,杨召阳,刘嘉琦, 邢泽宇，刘刚，张宏图，王翔*. 乳腺颗粒细胞瘤1例并文献回顾[J]. 癌症进展,2021,19(11):1186-1188. DOI:10.11877/j.issn.1672-1535.2021.19.11.26. (通讯作者)

5. 王翔. 新冠病毒来袭,肿瘤患者如何应对?[J]. 健康指南,2020(3):50-51. (第一作者)

6. 王翔. 性激素与乳腺癌之间的关系[J]. 抗癌之窗,2019(4):20-22. (第一作者)

7. 冯轲昕,王翔,王昕. 增殖细胞核抗原Ki-67及其在新辅助化疗前后的变化与乳腺癌预后的关系[J]. 癌症进展,2019,17(13):1494-1497,1582. DOI:10.11877/j.issn.1672-1535.2019.17.13.02. (通讯作者)

8. 张梦璐,王昕,邢泽宇,等. 雄激素受体与Luminal型乳腺癌内分泌耐药的研究进展[J]. 癌症进展,2018,16(12):1455-1457,1488. DOI:10.11877/j.issn.1672-1535.2018.16.12.03. (通讯作者)

9. 王杰,于伟杰,王昕,等. 乳腺派杰氏病的临床病理特征及预后[J]. 中华肿瘤杂志,2018,40(7):523-527. DOI:10.3760/cma.j.issn.0253-3766.2018.07.008. (通讯作者)

10. 王文彦,王昕,王翔. 循环肿瘤DNA检测在乳腺癌诊治中的临床应用[J]. 转化医学电子杂志,2017,4(9):13-17. DOI:10.3969/j.issn.2095-6894.2017.09.003. (通讯作者)

11. 王文彦,王昕,高纪东,等. 674例乳腺导管内乳头状肿瘤的临床病理特征及预后分析[J]. 中华肿瘤杂志,2017,39(6):429-433. DOI:10.3760/cma.j.issn.0253-3766.2017.06.006. (通讯作者)

12. 张柏林,吴金其,郑荣寿,等. 女性乳腺癌发病危险因素的病例-对照研究[J]. 癌症进展,2017,15(4):395-398. DOI:10.11877/j.issn.1672-1535.2017.15.04.12. (通讯作者)

13. 王翔，王淑莲，王昕，国内乳腺癌治疗中的常见误区，中华医学杂志，2014，94(4)：244-245 (第一作者)

14. 王翔，单毅，赵东兵，邵永孚，EBCTCG有关早期乳腺癌辅助化疗和内分泌治疗的最新荟萃分析结果，科学观察，2007，(06)：43-44(第一作者)

15. 王翔，邵永孚，吴铁成，三苯氧胺及ATLAS试验现状，癌症进展，2004，(05)：405-407(第一作者)

16. 王文彦，张柏林，徐晓洲，王昕，张频，王翔(*)，新辅助化疗后腋窝淋巴结分期和病理缓解状态对乳腺癌患者预后的影响，中华肿瘤杂志，2015，(3)：195-199(通讯作者)

17. 王昕，王文彦，王杰，宋颖，王翔(*)，叶枫，磁共振成像引导下乳腺微小病变穿刺的临床应用初探，中华肿瘤杂志，2015，(9)：682-685(通讯作者)

18. 王慧，王靖，高纪东，方仪，王仲照，王翔(*)，乳腺癌非前哨淋巴结转移的预测因素分析，中华肿瘤防治杂志，2014，(22)：1825-1828(通讯作者)

19. 徐发良，王文彦，王翔(*)，早期乳腺癌局部肿块切除术后的保乳手术，中国微创外科杂志，2014，(07)：577-579(通讯作者)

20. 王昕，王文彦，徐晓洲，张柏林，王翔(*)，局部晚期乳腺癌分子病理分型与新辅助化疗疗效的相关性及预后因素分析，中国医刊，2014，(05)：41-44(通讯作者)

21. 王昕，王翔(*)，王文彦，高纪东，宣立学，李晔雄，冯勤付，术中电子线放疗在早期乳腺癌保乳手术瘤床加量放疗中的应用分析，中国医刊，2013，(11)：35-37(通讯作者)

22. 王昕，冯勤付，王文彦，高纪东，宣立学，王靖，李晔雄，王翔(*)，术中放疗技术应用于早期乳腺癌保乳手术的临床分析，中华医学杂志，2013，93(48)：3861-3863(通讯作者)

23. 郭春光，刘骞，解亦斌，王翔(*)，影响乳腺癌前哨淋巴结数目的临床病理特征分析，基础医学与临床，2012，(06)：693-696(通讯作者)

24. 郭春光，刘骞，高纪东，裴伟，王翔(*)，早期乳腺癌前哨淋巴结转移的影响因素分析，中国医药，2012，07(6)：728-729(通讯作者)

25. 张慧明，王翔(*)，新辅助治疗对保乳手术的影响，中国微创外科杂志，2011，(03)：268-271(通讯作者)

26. 徐晓洲，张柏林，王翔(*)，B超引导下真空辅助旋切系统用于乳腺疾病诊治价值研究，中国实用外科杂志，2009，(12)：1028-1029(通讯作者)

27. 高纪东，张保宁，王翔(*)，王靖，毕晓峰，65岁以上老年女性乳腺癌临床病理特点及预后分析，中华医学杂志，2009，89(2)：83-86(通讯作者)

28. 高纪东，王靖，冯晓丽，钟宇新，王翔(*)，5758例女性乳腺癌激素受体状态及其相关因素分析，中华肿瘤杂志，2009，31(9)：683-686(通讯作者)

29. 王靖，王翔(*)，晏晓青，由磊，乳腺癌改良根治术后同时应用腹壁下动脉穿支皮瓣游离移植再造乳房，中华医学杂志，2005，(47)：3359-3361(通讯作者)

作为早期乳腺癌临床试验协作组(Early Breast Cancer Trialists' Collaborative Group，EBCTCG)

成员共同发表文章

(1) EBCTCG. et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.N Engl J Med. 2017 Nov 9;377(19):1836-1846. (影响因子：72.406)

(2) EBCTCG. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.Lancet. 2015 Oct 3;386(10001):1341-1352. (影响因子：47.831)

(3) EBCTCG. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.Lancet. 2015 Oct 3;386(10001):1353-1361.(影响因子：47.831)

(4) EBCTCG.et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.Lancet. 2014 Jun 21;383(9935):2127-35.(影响因子：47.831)

(5) EBCTCG. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.Lancet. 2012 Feb 4;379(9814):432-44.(影响因子：47.831)

(6) EBCTCG. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet. 2011 Nov 12;378(9804):1707-16.(影响因子：47.831)

(7) EBCTCG. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.Lancet. 2011 Aug 27;378(9793):771-84.(影响因子：47.831)

(8) EBCTCG. et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.Lancet. 2008 Jan 5;371(9606):29-40.(影响因子：47.831)

(9) EBCTCG. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005 Dec 17;366(9503):2087-106.(影响因子：47.831)

(10) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005 May 14-20;365(9472):1687-717.(影响因子：47.831)

以上作品原文全部来源互联网,如有侵权请联系删除